Figure 1. Genomic changes in SCRIB associated with human breast cancer.

(A) The cBioPortal was used to detect genomic alterations and gene expression changes (mutations, copy number alterations, mRNA expression) in the SCRIB gene among 748 human breast tumors. (B) SCRIB gene expression in breast cancer molecular subtypes. Normalized and median-centered SCRIB gene expression levels were compared in breast cancer molecular subtypes as defined in a publically available dataset of breast tumors. SCRIB expression is expressed as log2 values. Mean SCRIB expression between tumors within each subtype is represented by a black line. Lines above the graph represent statistical significance of variance between subtypes as determined by Kruskall-Wallace non-parametric method. Asterisks represent p values; *** = p<0.001; ** = p<0.01; * = p<0.05; n.s. = p>0.05. (C) Analysis of SCRIB mRNA across TNBC subtypes. Gene expression (GE) profiles were obtained from 21 publicly available data sets that contained 3,247 primary human breast cancers. Gene expression for SCRIB (212556_at) was extracted and used for all comparisons. The lower panel displays p-values representing the difference between SCRIB expression in each subgroup (D) SCRIB expression stratifies overall survival in breast cancer. Kaplan-Meier estimates of overall survival were calculated in a publically available integrated multi-study breast cancer transcriptomic dataset through the KMplotter tool. The upper quartile of SCRIB expression used to dichotomise data into high versus low expression groups. Number of total patients are shown, significance of differences in survival curves are determined by log-rank p-values and hazard ratios are calculated by cox regression analysis. (E) (i) Human breast tumor with predominantly membrane SCRIB localization. (ii) Human breast tumor with membrane and cytosolic SCRIB localization. (iii) Human breast tumor with predominantly cytosolic SCRIB localization.